Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,216 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05786742Recruiting
Radiation plan test for early prostate cancer with a boost
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
QuébecAges 18–95 - NCT06982469Recruiting
High-dose radiation for prostate cancer return after surgery
This trial tests a high-dose radiation treatment (brachytherapy) that places tiny radioactive seeds directly into the area where your prostate was. It is for men whose prostate cancer has returned only in that area after having their prostate removed.
Pamplona, Foral Community of NavarreAges 18–80 - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT04992728Recruiting
Testing a special prostate MRI to match cancer maps
This study uses a special kind of MRI to better “map” prostate cancer inside the prostate. Researchers compare the MRI results with the detailed tissue exam after prostate surgery to see how accurate the imaging is.
La Jolla, CaliforniaAges 18 years+ - NCT06171269Recruiting
MRI-guided radiation dose reduction for prostate cancer
This trial tests whether using MRI scans to guide radiation can allow lower doses to the healthy parts of the prostate, potentially reducing side effects. It is for men with intermediate- or high-risk prostate cancer that can be seen on MRI and has not spread.
Chicago, IllinoisAges 18 years+ - NCT06523634Recruiting
SBRT for rising PSA after prostate removal
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
AalstAges 18 years+ - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT07202247RecruitingPhase 2
Improving heart health in prostate cancer patients on hormone therapy
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
Duarte, CaliforniaAges 30–79 - NCT07391982Recruiting
Short course MRI-guided radiation for prostate cancer
This trial tests a shorter radiation plan using an MRI machine to guide treatment. The goal is to see if two high-dose sessions work just as well as longer treatment, with fewer side effects. It is for men with low or intermediate risk prostate cancer.
AmsterdamAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
San Diego, CaliforniaAges 18–90 - NCT05647564Recruiting
PET/CT scan to study why prostate cancer resists treatment
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Madison, WisconsinAges 18 years+ - NCT06626386Recruiting
Prostate cancer screening with a finger-prick test
This trial is testing a simple finger-prick blood test to measure prostate-specific antigen (PSA) for prostate cancer screening. It aims to make screening easier and more accessible.
Düsseldorf, North Rhine-WestphaliaAges 45–70 - NCT07293585RecruitingPhase 3
Precision radiation to protect erectile function in prostate cancer
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
Los Angeles, CaliforniaAges 18 years+ - NCT06202820Recruiting
Heart health monitoring for men on hormone therapy
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
Boston, MassachusettsAges 18 years+ - NCT06946771Recruiting
MRI and prostate lesions: understanding diagnosis and prognosis
This trial uses MRI scans to study prostate lesions and see how they relate to diagnosis, pathology, and long-term outcomes. It may help patients with concerns about prostate health get more detailed imaging.
Wuhan, HubeiAges 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05974774RecruitingPhase 3
Intermittent hormone therapy for metastatic prostate cancer with low PSA
This trial studies whether taking hormone therapy in breaks (instead of continuously) can work for people with metastatic prostate cancer whose PSA is very low after prior treatment with hormone-deprivation plus an AR pathway inhibitor. It may help reduce time on treatment while still keeping cancer controlled.
CopenhagenAges 18–100 - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT06280781Recruiting
Long-term active surveillance for prostate cancer
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
Ascot, BerkshireAges 18 years+ - NCT06591819RecruitingPhase 2
Shorter pelvic radiation with HDR boost for prostate cancer
This trial tests a shorter course of radiation therapy (hypofractionated whole-pelvis radiation) combined with a high-dose-rate (HDR) brachytherapy boost for men with high-risk or unfavorable intermediate-risk prostate cancer. The goal is to see if this approach controls cancer while possibly reducing side effects.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT06841211Recruiting
Optimizing prostate biopsy for multiple MRI lesions
This study aims to find the best way to take tissue samples (biopsies) from the prostate when MRI shows more than one suspicious spot. It will help doctors know exactly where to biopsy to reduce false negatives and avoid missing cancer.
Beijing, Beijing MunicipalityAges 18–85
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,216 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.